To compare differences in the immune microenvironment between the high and low TP53 score groups of patients with BLCA, We used CyTOF to analyze CD45 + cells obtained from 37 BLCA samples (high TP53 score group = 18, low TP53 score group = 19). This evidence concerns the gene TP53 and bladder transitional cell carcinoma.